22 January 2021
Eli Lilly announced that its antibody drug, Bamlanivimab (LY-CoV555), significantly reduced the risk of contracting Covid-19 among residents and staff at nursing homes and assisted facilities. The Phase III BLAZE-2 Covid-19 prevention trial was conducted along with the National Institutes of Health (NIH), and the Covid-19 Prevention Network (CoVPN).
Moderna announced that its first participant has been dosed with its Covid-19 vaccine candidate, mRNA-1273, in a Phase I/II study in Japan. Takeda is supporting Moderna in carrying out this Japanese vaccine trial.
The Russian Direct Investment Fund announced that the UAE Ministry of Health and Prevention has authorised the use of the Russian Sputnik V vaccine in the country. The vaccine received approval on the basis of the results of Russia’s Phase III clinical trials that enrolled over 33,000 subjects.
EuBiologics announced that its Covid-19 vaccine candidate EuCorVac-19 has been approved for Phase I/II clinical trials by the South Korean Ministry of Food and Drug Safety. This allows EuBiologics to start a Phase I trial in South Korea in 50 healthy adults aged between 19 to 50 years; the trial will evaluate the safety, tolerance and efficacy of the vaccine in the participants.
